TY - JOUR
T1 - Clinicopathological correlation of aspartate aminotransferase-to-platelet ratio (APRI) and aspartate aminotransferase-to-alanine aminotransferase ratio (AAR) with survival in esophageal carcinoma patients
T2 - a retrospective cohort analysis of 951 patients
AU - Zafar, Muhammad Talha
AU - Zia, Beenish Fatima
AU - Khalid, Saleha Rashid
AU - Bai, Jharna
AU - Memon, Zahid Ali
AU - Jan, Zaka Ullah
AU - Jadoon, Sarosh Khan
AU - Khan, Noman Ahmed
AU - Kajal, Diksha
AU - Ali, Farukh
AU - Kirmani, Tooba Ahmed
AU - Asghar, Muhammad Sohaib
N1 - Publisher Copyright:
© 2023 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
PY - 2023/4/1
Y1 - 2023/4/1
N2 - Background: Esophageal cancer is the eighth most prevalent cancer globally. Previously, several biomarkers have been used to predict the prognosis, although with variable reliability. Interestingly, it is noted that changes in liver function tests levels before and after neoadjuvant treatment are predictive in terms of cancer recurrence. Objectives: The objectives of the current study were to associate novel markers, including aspartate aminotransferase-to-platelet ratio (APRI) and aspartate aminotransferase-to-alanine aminotransferase ratio (AAR) with survival in esophageal malignancy. Materials and Methods: A retrospective study in a tertiary care hospital (single-center) included 951 patients having diagnosed esophageal carcinoma of any age group. Results: The median (interquartile range) age of study participants were 50 (38-60) years, including 43% males and 57% female patients, while the median (interquartile range) levels of AAR and APRI were 0.97 (0.81-1.25) and 0.19 (0.13-0.29), respectively. AAR was found to be higher in dysphagia for solids only and dysphagia for both liquids and solids rather than liquids only (P = 0.002), while other associations included well-differentiated tumor grade (P = 0.011), finding of esophageal stricture on esophagogastroduodenoscopy (P = 0.015), and characteristic of mass on computerized tomography scan being both circumferential and mural (P = 0.005). APRI was found to be higher in adenocarcinoma (P = 0.038), and finding of circumferential ± ulcerated mass on esophagogastroduodenoscopy (P < 0.001). On survival analysis, adenocarcinoma (P < 0.001), luminal narrowing (P = 0.002), AAR greater than 1.0 (P = 0.006), and APRI greater than 0.2 (P = 0.007) were found to be poor survival predictors. On Cox proportional hazards regression, APRI was found to be more associated with poor survival than AAR (Hazard ratio: 1.682, 1.208-2.340, P = 0.002). Conclusion: This study correlated clinical and pathological features of esophageal malignancy with noninvasive markers of hepatic function.
AB - Background: Esophageal cancer is the eighth most prevalent cancer globally. Previously, several biomarkers have been used to predict the prognosis, although with variable reliability. Interestingly, it is noted that changes in liver function tests levels before and after neoadjuvant treatment are predictive in terms of cancer recurrence. Objectives: The objectives of the current study were to associate novel markers, including aspartate aminotransferase-to-platelet ratio (APRI) and aspartate aminotransferase-to-alanine aminotransferase ratio (AAR) with survival in esophageal malignancy. Materials and Methods: A retrospective study in a tertiary care hospital (single-center) included 951 patients having diagnosed esophageal carcinoma of any age group. Results: The median (interquartile range) age of study participants were 50 (38-60) years, including 43% males and 57% female patients, while the median (interquartile range) levels of AAR and APRI were 0.97 (0.81-1.25) and 0.19 (0.13-0.29), respectively. AAR was found to be higher in dysphagia for solids only and dysphagia for both liquids and solids rather than liquids only (P = 0.002), while other associations included well-differentiated tumor grade (P = 0.011), finding of esophageal stricture on esophagogastroduodenoscopy (P = 0.015), and characteristic of mass on computerized tomography scan being both circumferential and mural (P = 0.005). APRI was found to be higher in adenocarcinoma (P = 0.038), and finding of circumferential ± ulcerated mass on esophagogastroduodenoscopy (P < 0.001). On survival analysis, adenocarcinoma (P < 0.001), luminal narrowing (P = 0.002), AAR greater than 1.0 (P = 0.006), and APRI greater than 0.2 (P = 0.007) were found to be poor survival predictors. On Cox proportional hazards regression, APRI was found to be more associated with poor survival than AAR (Hazard ratio: 1.682, 1.208-2.340, P = 0.002). Conclusion: This study correlated clinical and pathological features of esophageal malignancy with noninvasive markers of hepatic function.
KW - esophagus
KW - histopathology
KW - malignancy
KW - mortality
KW - survival
UR - http://www.scopus.com/inward/record.url?scp=85161599363&partnerID=8YFLogxK
U2 - 10.1097/MS9.0000000000000311
DO - 10.1097/MS9.0000000000000311
M3 - Article
AN - SCOPUS:85161599363
SN - 2049-0801
VL - 85
SP - 706
EP - 711
JO - Annals of Medicine and Surgery
JF - Annals of Medicine and Surgery
IS - 4
ER -
